{"id":"W4308405423","doi":"10.1016/s0140-6736(22)02034-7","title":"Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial","year":2022,"lang":"en","type":"article","venue":"The Lancet","topic":"Nitric Oxide and Endothelin Effects","field":"Medicine","cited_by":227,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Janssen Biotech; Idorsia Pharmaceuticals; Bausch Health; Menarini Group; Servier; Gedeon Richter; Amgen; High Blood Pressure Research Council of Australia; Novo Nordisk; Teva Pharmaceutical Industries; ReCor Medical; International Society of Hypertension; Ionis Pharmaceuticals; FibroGen; Alnylam Pharmaceuticals; AstraZeneca; Bristol-Myers Squibb; Abbott Laboratories","keywords":"Medicine; Placebo; Blood pressure; Ambulatory blood pressure; Diuretic; Clinical endpoint; Endothelin receptor antagonist; Internal medicine; Randomized controlled trial; Endothelin receptor","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001766386,0.0002519728,0.0009046397,0.0001008502,0.0006080251,0.00004645772,0.0002920679,0.00006503435,0.0002933748],"category_scores_gemma":[0.0007264772,0.0001602476,0.0003435677,0.0002357749,0.00007636114,0.00005078709,0.0001348923,0.0004232479,0.00004654824],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001109839,"about_ca_system_score_gemma":0.00009047406,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004037354,"about_ca_topic_score_gemma":0.000009244886,"domain_scores_codex":[0.9975576,0.0003498987,0.0005228303,0.0004210075,0.0005838033,0.0005648634],"domain_scores_gemma":[0.9973757,0.001441929,0.0002031483,0.0007546673,0.0000758939,0.000148692],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9131199,0.001124175,0.00003505485,0.0000742331,0.0001675269,0.0001950889,0.0002269294,0.00003501816,0.04901809,0.0002227489,0.0269332,0.008848035],"study_design_scores_gemma":[0.8283422,0.002836722,0.00004844966,0.00004192888,0.0004319936,0.0002008981,0.0004591953,0.00320839,0.001606195,0.000496145,0.1621031,0.0002248045],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9780491,0.001449815,0.001130953,0.006856871,0.001396063,0.008890589,0.0006417519,0.0002286173,0.001356239],"genre_scores_gemma":[0.9841098,0.0002990421,0.003350907,0.004566671,0.003730043,0.001475716,0.0002389702,0.00007750199,0.002151397],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1351699,"threshold_uncertainty_score":0.6534708,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06100171892594759,"score_gpt":0.3257877469879694,"score_spread":0.2647860280620218,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}